Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment

Nov 18, 2020

|

NEW YORK – Qiagen said on Wednesday that it has forged a collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic to identify patients with squamous cell head and neck cancer caused by specific human papillomavirus (HPV) infections, who may be eligible for BioNTech's investigational cancer treatment BNT113.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

A Real-Time-Assay for the fast and gel-free detection of Rhesus Weak D Type 1/1.1 to Type 3

Fast Real-Time PCR Detection of HLA-B*27 Directly from Blood Using a Specialized Stabilizing Reagent

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Mar

29

Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar

31

Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.

Apr

06

Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

Menu

Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment

To read the full story....

Breaking News

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Sponsorships